The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery
Open accessAbstract
Polymer-based microparticles are in clinical use mainly for their ability to provide controlled release of peptides and compounds, but they are also being explored for their potential to deliver vaccines and drugs as suspensions directly into mucosal sites. It is generally assumed that uptake is mediated by epithelial M cells, but this is often not directly measured. To study the potential for optimizing M cell uptake of polymer microparticles in vivo, we produced sub-micron size PLGA particles incorporating a recombinant protein. This recombinant protein was produced with or without a c-terminal peptide previously shown to have high affinity binding to Claudin 4, a protein associated with M cell endocytosis. While the PLGA nanoparticles incorporate the protein throughout the matrix, much of the protein was also displayed on the surface, allowing us to take advantage of the binding activity of the targeting peptide. Accordingly, we found that instillation of these nanoparticles into the nasal passages or stomach of mice was found to significantly enhance their uptake by upper airway and intestinal M cells. Our results suggest that a reasonably simple nanoparticle manufacture method can provide insight into developing an effective needle-free delivery system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CPE30, the C-terminal 30 amino acid part of CPE, was coated to PLGA NPs, which increased the uptake by upper airways when administered intranasally or by intestinal M cells after ingestion [101].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [101]
In the citing paper
“The latter functions as a receptor for Clostridium perfringens enterotoxin (CPE) and has been recent focus for targeting approaches [101].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clostridium perfringens Enterotoxin Fragment Removes Specific Claudins from Tight Junction Strands
Sonoda, N., Furuse, M., Sasaki, H., Yonemura, S., Katahira, J., Horiguchi, Y., & Tsukita, S. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.147.1.195 · Cited by 612
Rahner, C., Mitic, L. L., & Anderson, J. M. (2001) · Gastroenterology · doi:10.1053/gast.2001.21736 · Cited by 546
Jiang, W., Rk, G., DESHPANDE, M., & Schwendeman, S. P. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.09.003 · Cited by 480
Eldridge, J. H., Staas, J. K., Meulbroek, J. A., Tice, T. R., & Gilley, R. M. (1991) · Infection and Immunity · doi:10.1128/iai.59.9.2978-2986.1991 · Cited by 365
Katahira, J., Inoue, N., Horiguchi, Y., Matsuda, M., & Sugimoto, N. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.136.6.1239 · Cited by 278
Katahira, J., Sugiyama, H., Inoue, N., Horiguchi, Y., Matsuda, M., & Sugimoto, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26652 · Cited by 273
Sansonetti, P. J., & Phalipon, A. (1999) · Seminars in Immunology · doi:10.1006/smim.1999.0175 · Cited by 269
How to achieve sustained and complete protein release from PLGA-based microparticles?
Giteau, A., Venier‐Julienne, M., Aubert‐Pouëssel, A., & Benoît, J. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.11.012 · Cited by 268
Crotts, G., & Park, T. G. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809008253 · Cited by 263
Blanco, D., & Alonso, M. J. (1998) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(98)00011-3 · Cited by 252
Pappo, J., & Ermak, T. H. (1989) · PubMed Central · Cited by 216
Chong, C. S. W., Cao, M., Wong, W. W., Fischer, K. P., Addison, W. R., Kwon, G. S., Tyrrell, D. L., & Samuel, J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.09.014 · Cited by 195
Quantifying drug release from PLGA nanoparticulates
Corrigan, O. I., & Li, X. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.04.004 · Cited by 195
Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination
Slütter, B., Plapied, L., Fievez, V., Alonso, M. J., Rieux, A. D., Schneider, Y., van Riet, E., Jiskoot, W., & Véronique Préat, A. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.05.011 · Cited by 192
Nochi, T., Yuki, Y., Matsumura, A., Mejima, M., Terahara, K., Kim, D. Y., Fukuyama, S., Iwatsuki‐Horimoto, K., Kawaoka, Y., Kohda, T., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070607 · Cited by 177
Mao, S., Shi, Y., Li, L., Xu, J., Schaper, A., & Kissel, T. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.06.008 · Cited by 169
Shakweh, M., Besnard, M., Nicolas, V., & Fattal, E. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.04.006 · Cited by 161 · cited 3×
“First, the particles are in a narrow size range less than 1 μm, which has been suggested by our own studies and the scientific literature [21,22,27] as being anoptimal size range formucosal M cell uptake.”
Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination
Fiévez, V., Plapied, L., Rieux, A. D., Pourcelle, V., Freichels, H., Wascotte, V., Vanderhaeghen, M.-L., Jérôme, C., Vanderplasschen, A. F. C., Marchand‐Brynaert, J., et al. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.04.009 · Cited by 158
Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo
Foster, N. M. (1998) · Vaccine · doi:10.1016/s0264-410x(97)00222-3 · Cited by 146
M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B
Gupta, P. N., Khatri, K., Goyal, A. K., Mishra, N., & Vyas, S. P. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701637982 · Cited by 136
Targeting to intestinal M cells.
Jepson, M. A., Clark, M. A., Foster, N. M., Mason, C. M., Bennett, M. K., Simmons, N. L., & Hirst, B. H. (1996) · Europe PMC (PubMed Central) · Cited by 133
Gaumet, M., Gurny, R., & Delie, F. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.11.015 · Cited by 115
Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells
Ermak, T. H., Dougherty, E. P., Bhagat, H. R., Kabók, Z., & Pappo, J. (1995) · Cell and Tissue Research · doi:10.1007/bf00318501 · Cited by 110
M cell-targeted DNA vaccination
Wu, Y., Wang, X., Smith, K. C., Haddad, A., Walters, N., & Pascual, D. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161204098 · Cited by 109
Igartúa, M., Hernández, R. M., Esquisabel, A., Rodríguez‐Gascón, A., Calvo, M. B., & Pedraz, J. L. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00077-7 · Cited by 105
Woo, B. H., Jiang, G., Jo, Y. W., & DeLuca, P. P. (2001) · Pharmaceutical Research · doi:10.1023/a:1013090700443 · Cited by 103
Manocha, M., Pal, P. C., Chitralekha, K. T., Thomas, B. E., Tripathi, V., Gupta, S. D., Paranjape, R., Kulkarni, S., & Rao, D. N. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.06.031 · Cited by 103
Coombes, A. G. A., Yeh, M., Lavelle, E. C., & Davis, S. S. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00006-6 · Cited by 103
Shi, L., Caulfield, M. J., Chern, R. T., Wilson, R. A., Sanyal, G., & Volkin, D. B. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10042 · Cited by 96
Xie, S., Wang, S., Zhao, B., Han, C., Wang, M., & Zhou, W. (2008) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2008.08.018 · Cited by 93
Lo, D. D. (2003) · International Immunology · doi:10.1093/intimm/dxh011 · Cited by 83
Self-citationSpecific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages
Brandhonneur, N., Chevanne, F., Vié, V., Frisch, B., Primault, R., Le Potier, M.-F., & Le Corre, P. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.11.013 · Cited by 75
Stabilization of Tetanus Toxoid Encapsulated in PLGA Microspheres
Jiang, W., & Schwendeman, S. P. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800027f · Cited by 69
Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66
Rosas, J. E., Hernández, R. M., Rodríguez‐Gascón, A., Igartúa, M., Guzmán, F., Patarroyo, M. E., & Pedraz, J. L. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00192-x · Cited by 67
Ling, J., Liao, H., Clark, R. T., Wong, M. S. M., & Lo, D. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803548200 · Cited by 66
Self-citationSuzuki, H., Sekine, S., Kataoka, K., Pascual, D. W., Maddaloni, M., Kobayashi, R., Fujihashi, K., Kozono, H., McGhee, J. R., & Fujihashi, K. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.037 · Cited by 63
Improvement of a bovine serum albumin microencapsulation process by screening design
Haushey, L. A., Bolzinger, M., Bordes, C., Gauvrit, J. Y., & Briançon, S. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.05.067 · Cited by 53
Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology
Román, B. S., Irache, J. M., GOMEZ, S., Tsapis, N., Gamazo, C., & Espuelas, S. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.03.015 · Cited by 51
Transfection Ability and Intracellular DNA Pathway of Nanostructured Gene-Delivery Systems
Zhang, X., Sharma, K. K., Boeglin, M., Ogier, J., Mainard, D., Voegel, J., Mély, Y., & Benkirane-Jessel, N. (2008) · Nano Letters · doi:10.1021/nl801379y · Cited by 50
Preparation and characterization of gelatin surface modified PLGA microspheres
Tsung, M., & Burgess, D. J. (2001) · AAPS PharmSci · doi:10.1208/ps030211 · Cited by 44
Surface‐functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium
Sundaram, S., Roy, S. K., Ambati, B. K., & Kompella, U. B. (2009) · The FASEB Journal · doi:10.1096/fj.09-129825 · Cited by 43
Rubas, W., Banerjea, A. C., Gallati, H., Speiser, P. P., & Joklik, W. K. (1990) · Journal of Microencapsulation · doi:10.3109/02652049009021848 · Cited by 34
Differential expression of claudin-4 between intestinal and diffuse-type gastric cancer
Kuo, W., Lee, L., Wu, C., Wang, C., Yu, J., Liang, Y. J., Lo, C.-H., Huang, K.-H., & Hwang, T. (2006) · Oncology Reports · doi:10.3892/or.16.4.729 · Cited by 32
Zhang, J., Chen, D., Wang, S., & Zhu, K. J. (2005) · Journal of Microencapsulation · doi:10.1080/02652040500098994 · Cited by 32
Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue
Fujimura, Y., Akisada, T., Harada, T., & Haruma, K. (2006) · Medical Molecular Morphology · doi:10.1007/s00795-006-0335-6 · Cited by 30
Zhao, A., & Rodgers, V. G. J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.03.018 · Cited by 30
Betancourt, T., Shah, K., & Brannon‐Peppas, L. (2008) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-008-3594-z · Cited by 28
Rafati, H. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00134-5 · Cited by 24
Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres
Brandhonneur, N., Loizel, C., Chevanne, F., Wakeley, P. R., Jestin, A., Potier, M. F. L., & Corre, P. L. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.01.020 · Cited by 10
Cited by
Sorted by citations
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Breton, A. L., & Véronique Préat, A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 4,006
The intestinal epithelium: central coordinator of mucosal immunity
Allaire, J. M., Crowley, S. M., Law, H. T., Chang, S.-Y., Ko, H.-J., & Vallance, B. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.002 · Cited by 933
Basics and Recent Advances in Peptide and Protein Drug Delivery
Bruno, B. J., Miller, G. D., & Lim, C. S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.104 · Cited by 771
Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium
Mabbott, N. A., Donaldson, D. S., Ohno, H., Williams, I. R., & Mahajan, A. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.30 · Cited by 721
The endocytosis and intracellular fate of nanomedicines: Implication for rational design
Kou, L., Sun, J., Zhai, Y., & He, Z. (2013) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2013.07.001 · Cited by 588
Metadata
- Authors
- Rajapaksa, T. E., Stover-Hamer, M., Fernandez, X., Eckelhoefer, H. A., & Lo, D. D.
- Affiliations
- University of California, Riverside (US)
- Corresponding author
- Lo, David D.
- ORCID
- Lo, David D.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 142
- Issue
- 2
- Pages
- 196-205
- ISSN
- 0168-3659 (ISSN-L)
- PMC
- PMC2823968
- OpenAlex
- W1973426656
- Cited by
- 137
- References
- 50
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 8 · 2023: 11 · 2022: 6 · 2021: 5 · 2020: 12 · 2019: 9 · 2018: 9 · 2017: 10 · 2016: 8 · 2015: 8 · 2014: 12 · 2013: 11 · 2012: 14
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Foundation for the National Institutes of Health
- Harvard University
- National Institute of Allergy and Infectious Diseases (AI73689, R01AI063426, R43AI058434, R21AI073689)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- claudin-4, M cells, PLGA nanoparticles, targeted drug delivery, mucosal drug delivery, nasal instillation, upper airway, vaccine delivery
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Biological Transport, Cell Line, Cricetulus, Drug Carriers, Cricetinae, Hemagglutinins, Membrane Proteins, Mucous Membrane, Influenza A virus, Peyer's Patches, Polyglycolic Acid, Recombinant Proteins, CHO Cells, Lactic Acid, Mice, Nanoparticles, Claudin-4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
